I found a great experience of daily weight loss pills that it helped people get rid of pounds and reduce blood sugar levels, making the competitor join the new wave of drugs that fight obesity and diabetes.
People who took 36 mg pills from OrforiPron lost an average of 7.3 kg (16 pounds) over nine months, according to results from a clinical trial from the third stage that the manufacturer of the drug, ELI Lilly, on Thursday.
The trial, which joined 559 people with type 2 diabetes from the United States, China, India and Japan MexicoIt was also found that daily birth control pills reduced blood sugar levels, in some cases that turn them down to the official threshold of diabetes.
The results of the experiment have been eagerly awaited by healthy researchers because OrforiPron is the first daily version of the GLP-1, which is the drug used to inject popular weight loss such as OzemPIC and Wegovy.
“As a comfortable pill once a day, Orforglipron may provide a new option, and if approved, it can be easily manufactured and widely launched for use by people around the world,” said David Rex, CEO of Eli Lily.
In a statement accompanying the results, the company said that the drug had achieved safety, endurance, glucose control and weight loss.
While the popularity of weight loss has increased, health officials believe that daily medication pill versions can allow more people to control their weight and blood sugar. In Britain, two -thirds of adults increase either weight gain or live with obesity and more than 5 million people with type 2 diabetes.
The 40 -week experiment showed that eating daily pill of 3 mg, 12 mg or 36 mg reduced blood sugar by 1.2 % to 1.5 %. During the same period, the participants saw their weight decreased by 4.5 % on 3 mg pills, 5.8 % on 12MG and 7.6 % on the 36MG pill.
After promoting the newsletter
The results will be presented at an American meeting Diabetic In the June Association before publishing in the Journal of Lacality Review. The company said that it will apply for approval to drug marketing to manage weight later this year and type 2 diabetes next year.
“These are important results,” said Naveeed Sattar, a professor of cardiovascular medicine at the University of Glasgow.
